AI Stock Analysis: Is RXRX a Smart Buy right now?

June 25, 7:00 am

Recursion Pharmaceuticals is a biotechnology and life sciences company that leverages advanced technologies and data analytics to accelerate drug discovery and development. The company's platform combines biology and machine learning to address complex diseases and uncover novel therapeutics. Its innovation-driven approach has propelled it into the spotlight in the pharmaceutical industry.

Price & AI Score for RXRX.

Fundamental Analysis

Recursion Pharmaceuticals has shown considerable growth in revenue and moderate growth in net income and EBITDA in the recent quarter. Their revenue for the last quarter was $14 million, an increase of 26.77% compared to the previous quarter. This uptick signifies robust quarter-over-quarter growth, affirming the company's accelerating capacity for monetization.

Year over year, the revenue increment is 13.69% against the same quarter last year, indicating steady yearly enhancements. However, the net income for the last quarter stands at $91 million, up 1.75% from the previous quarter, with a slight year-over-year drop of 39.87%, a red flag that requires investors to dig deeper into the factors causing this substantial decrement.

The EBITDA for the quarter clocked in at $89 million, marking a 5.23% rise from the preceding quarter, but a year-over-year plunge of 36.18%. The contrasting quarterly gains and annual losses in both net income and EBITDA suggest potential challenges in maintaining long-term profitability. Additionally, recent insider selling indicates a potentially bearish outlook from those close to the company, hinting at possible unease about future performance.

Technical Analysis

From a technical standpoint, Recursion Pharmaceuticals is exhibiting a bullish trend. Today's stock price of $9.51 reflects a 3.82% rise over the past month and a substantial 30.10% increase over the past year. This long-term upward movement underscores a positive sentiment surrounding the stock.

The stock's SMA10 is currently $9.26, slightly higher than the previous SMA10 of $9.23, reinforcing the potential upward trajectory. The RSI reading is 47.5, which sits in the neutral zone, providing neither a clear buy nor sell signal. Investors should watch for an RSI break above 70 or below 30 for a stronger momentum indication.

Alternative Data Analysis

In terms of alternative data, Recursion Pharmaceuticals has shown signs of expansion with a 12% increase in job postings over the past few months. The 37 open positions signal an aggressive growth posture, potentially bolstering future operations.

However, the outlook among employees remains neutral without clear enthusiasm for or against the company's direction. More concerning is the drop in website visitor traffic, down by 38% in the past couple of months, suggesting a decline in customer engagement or interest.

Conversely, the company's Twitter presence has grown by 6% to a total of 11,000 followers, pointing to increasing investor and public interest. The AltIndex AI score of 64, which integrates fundamental, technical, and alternative data indicators, suggests a buy signal.

Conclusion and Recommendation

In summary, Recursion Pharmaceuticals displays a mixture of strong immediate financial performances and some longer-term red flags. The compelling revenue growth (26.77% up quarter-over-quarter) and solid stock price performance (30.10% up year-over-year) are positive indicators. Yet, the significant annual declines in net income (down 39.87%) and EBITDA (down 36.18%) alongside insider selling raise some concerns about sustainable profitability.

On the technical front, the bullish trend in stock price and higher SMA10 are promising; however, the neutral RSI calls for cautious optimism. From an alternative data perspective, the hike in job listings and Twitter followers are positive, but the drop in web traffic should not be ignored.

Considering all the evaluations coupled with the AltIndex AI score of 64 suggesting a buy, a cautious "Buy" recommendation is advised, with close monitoring of financials and market conditions.

Disclaimer: This article, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current. Visit RXRX AI Stock Analysis for a more up-to-date analysis.

Get More Insights

Sign up and get access to a personalized dashboard, deeper insights, AI stock picks, stock alerts, weekly newsletter and much more.